Edward Libby, MD, Oncology, Seattle, WA, Seattle Cancer Care Alliance

EdwardNLibbyMD

OncologySeattle, WA

Hematologic Oncology

Associate Professor, Medicine, University of Washington School of Medicine

Overview of Dr. Libby

Dr. Libby received his B.S. from the University of Texas at El Paso and his M.D. from the University of Texas Health Science Center at Houston. He completed his Internal Medicine residency and chief residency at the University of New Mexico(UNM) in Albuquerque. He was a Fellow in Hematology at UNM and at UNC Chapel Hill.

Specialty & Clinical Expertise
Multiple myeloma, Plasma cell leukemia, Amyloidosis (all types), Waldenstrom’s macroglobulinemia, Plasmacytomas, POEMS Syndrome, smoldering multiple myeloma, MGUS.

Research Interests
Dr. Libby is the primary investigator for numerous Phase I,II and III clinical trials in multiple myeloma, amyloidosis and Waldenstrom's macroglobulinemia.

Education & Training

  • University of New Mexico HospitalFellowship
  • University of New Mexico HospitalResidency
  • University of Texas Medical School
    University of Texas Medical SchoolMedicalSchool

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2011 - 2022
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
    Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
    Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Treating Cancer Differently in Older PatientsSeptember 10, 2015

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    BCBS Blue Card PPO
    BCBS Texas BlueChoice
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    First Choice
    Great West PPO
    Humana ChoiceCare Network PPO
    Lovelace Health Plan PPO
    Multiplan PHCS PPO
    Multiplan PPO
    Premera BCBS Heritage & Heritage Plus 1
    Providence Health System Personal Option
    Regence Washington - Preferred Provider Network
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment